Using Angiomammography to Improve Breast Cancer Treatment Outcomes
Usefulness of Angiomammography for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer
This study is testing if a special imaging technique called angiomammography can help women with breast cancer see how well their chemotherapy is working after the second treatment cycle, so doctors can make changes if needed to improve their chances of recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | CHU de Quebec-Universite Laval Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Quebec City, Quebec) |
| Trial ID | NCT05402930 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of angiomammography in predicting pathological complete response (pCR) in women undergoing neoadjuvant chemotherapy for breast cancer. By assessing tumor response after the second cycle of chemotherapy, the study seeks to identify patients who may not be responding optimally to treatment, allowing for timely adjustments to their therapy. The goal is to enhance the chances of achieving pCR, which is associated with better prognostic outcomes. The study will involve female participants aged 18 and over with histologically confirmed breast cancer and measurable tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 and older with histologically proven breast cancer who are starting neoadjuvant chemotherapy.
Not a fit: Patients who are pregnant, have significant kidney failure, or have contraindications to MRI or contrast products may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for breast cancer patients, improving their chances of achieving a complete response to therapy.
How similar studies have performed: Previous studies have explored various imaging modalities for predicting treatment response in breast cancer, indicating that this approach has potential but may still be considered novel in the context of angiomammography.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female aged 18 and over * Histologically proven breast cancer by large gauge needle * No evidence of distant metastasis * Neoadjuvant chemotherapy with or without concomitant targeted therapy * Breast tumor initially measurable by clinical examination Exclusion Criteria: * Refusal to perform the biopsy or surgery * Pregnant or possibly pregnant woman * Usual contraindication to contrast product * Significant kidney failure * Allergy to contrast medium * frank hyperthyroidism * Usual contraindications to MRI
Where this trial is running
Quebec City, Quebec
- St-Sacrement Hospital — Quebec City, Quebec, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.